A comparative study of atorvastatin and rosuvastatin in dyslipidemia

Abstract

INTRODUCTIONWorldwide, hypercholesterolemia cause about 56% of ischemic heart disease and 18% of strokes, resulting to 4.4 million deaths annually. Hyperlipidemia and the rates of hypercholesterolemia (total cholesterol ≥201.1mg/dl) increased from 18% to 31% in adults aged 35-59. 1 Studies have shown that the risk of ischemic heart disease in individuals with hypercholesterolemia is about thrice as great as in those with normal plasma cholesterol level indicating that reduction in plasma cholesterol does reduce the risk of myocardial infraction. 2There is increasing evidence that Hyperlipidemia is a major cause of atherosclerosis and atherosclerosisassociated conditions, such as coronary heart disease (CHD), ischemic cerebrovascular disease and peripheral vascular disease and reduction of TC and LDL-C below 442.86mg/dl and 116mg/dl, respectively, lowers the incidence of CHD. The lifetime risk of developing CHD after 40 years of age is 49% in men and 32% in women. Even at 70 years of age, the risk is 35% for men and 24% for women. 3 The lifetime risk of developing CVD at 50 years of age is estimated to be 1 in 2 for men and 2 in 5 for women in USA only. 4 Numerous epidemiologic investigations have suggested that age, sex, elevated LDL-ABSTRACT Background: To compare the drugs: Atorvastatin (10mg) and Rosuvastatin (5mg) in patients with Dyslipidemia.Methods: This open-label, randomized, parallel group, comparative, prospective study of six months duration included 100 patients. The age group of patients varied from 30 to 69 years with dyslipidemia. Patients were divided in to 2 groups. 50 patients in group-1 received Atorvastatin 10mg once daily and 50 patients in group-2 received Rosuvastatin 5 mg once daily. The level of TC, TG, LDL, VLDL and HDL were assessed at baseline and at the end of 3 months and 6 months. Results: At 3 months, LDL was reduced significantly more with 5mg Rosuvastatin than with Atorvastatin 10 mg [43.68% vs. 40.74% (P 0.0049)]. At 6 months, Rosuvastatin 5mg reduced LDL significantly more than Atorvastatin 10 mg [48.69% vs. 43.85% (P 0.00)]. TC, HDL, TG and VLDL were more favourably modified by Rosuvastatin at 6 months (P <0.005). Reduction of total cholesterol levels in Rosuvastatin group was not statistically significant when compared with Atorvastatin group (P 0.103). Conclusions: Rosuvastatin 5mg was more efficacious than Atorvastatin 10mg for the improvement of lipid profile during the period of 6 months follow-up drug therapy in patients with dyslipidemia.

Comparing High Intensity With Low Intensity Statins in Achieving Optimal LDL Goals Among Coronary Artery Disease Patients in Suburban Population in South India

“…Thapa R et al [12] compared RSV5 with ATV10 and demonstrated significant change in LDL-C, TC, and HDL-C with both at the end of 3 rd and 6 th months. Similarly, percentage change in LDL-C, TC, and HDL-C with RSV5 was -48.69%, -35.01%, and + 25.56% respectively, while that with ATV10 was -43.85%, -34.94%, and + 8.71% respectively.…”

“…[7] Although there is abundant data analysing the efficacy of atorvastatin and rosuvastatin at different doses, in general, there is no analytical comparison of their lipid depleting effects in ACS patients. [8][9][10][11][12] It has been demonstrated in numerous studies that many high risk patients do not attain desired LDL-C control in spite of being treated with intensive statin therapy. [13,14] Thus, the aim of the present study was to analyse the control of LDL-C and high-density lipoprotein (HDL-C) levels after 12 weeks of statin therapy at different doses, in patients who had ACS and those who underwent revascularization with or without a prior episode of ACS.…”